

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**北 斗 嘉 藥 業 股 份 有 限 公 司**  
**BAYTACARE PHARMACEUTICAL CO., LTD.\***  
*(a joint stock limited company incorporated in the People's Republic of China)*  
**(Stock Code: 8197)**

**ADDITIONAL RESUMPTION GUIDANCE**

Reference is made to the announcements of the Company dated 26 September 2018, 10 October 2018, 21 December 2018 and 26 March 2019. Unless otherwise defined herein, capitalised terms used herein have the same meaning as defined in the announcement of the Company dated 26 March 2019.

As stated in the announcement of the Company dated 10 October 2018, the Company received a letter from the Stock Exchange dated 4 October 2018, in which the Stock Exchange set out the resumption guidance (the “**Resumption Guidance**”) for the Company. Please refer to the announcement of the Company dated 10 October 2018 for additional details.

On 3 April 2019, the Company received another letter from the Stock Exchange, pursuant to which the Stock Exchange set out the following additional resumption guidance:

- publish all outstanding financial results and address any audit modifications.

In the same letter dated 3 April 2019, the Stock Exchange indicated that the Stock Exchange may modify the resumption conditions/guidance that have been given and/or give further guidance if the situation changes.

Currently, the Company is using its best endeavours to confirm the resumption plan and resumption timetable as soon as possible. Once the resumption plan and resumption timetable are confirmed, the Company will comply with the relevant GEM Listing Rules requirement, including announcing the relevant resumption plan and resumption timetable, obtaining the approval of the Stock Exchange, and to the extent applicable, issuing a circular to shareholders and convening a special general meeting of shareholders to approve the transactions contemplated under the resumption plan.

The Company will keep the public informed of the progress on the fulfilment of the resumption conditions by making further periodic announcement.

Trading in the shares of the Company has been suspended with effect from 9am on 27 September 2018, and will continue to be suspended until further notice.

By Order of the Board  
**Baytacare Pharmaceutical Co., Ltd.\***  
*Executive Director*  
**Cui Bingyan**

Beijing, People's Republic of China, 9 April 2019

*As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao and Guo Aiqun; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Directors are Hui Lai Yam, Gao Zhikai and Chen Youfang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Company Announcements" page of the website of GEM at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of the publication and the Company's website at [www.baytacare.com](http://www.baytacare.com) from the date of this announcement.*

\* *for identification purposes only*